This consensus-based guidance, which includes an outline of eight key nutritional priorities to support patients on GLP-1 medications, reflects the top interdisciplinary recommendations to help clinicians support patients receiving GLP-1 receptor agonists for obesity care with evidence-based nutritional and behavioral strategies
Glucagon-like peptide agonists (GLP-1) drugs were originally approved to help manage Type 2 diabetes (T2D) and are now also being prescribed and used for weight management
Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohns disease
Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.
Thus, are changes in the gut bacterium itself beneficial to the host
For example, an increased risk of kidney stones could come from dehydration caused by lack of appetite, rather than an effect of the drug itself
